The EPS miss is significant for a micro-cap biotech, but the merger with Scipher Medicine is the primary catalyst. Monitor for merger closing updates and any regulatory milestones for nebokitug in RA. The stock's low liquidity and high volatility warrant caution.
Drug in focus
CMMB drug pipeline →nebokitug
◆ Mixed Named in this press release- Impact
- Phase
- Phase 2 (complete); preparing Phase 3
- Time to market
- At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
- Next catalyst
- None dated
What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 19 $2.09entry
- T+1 · 3mo ago −0.96%α −0.12% · $2.07
- T+5 · 3mo ago +23.92%α +24.31% · $2.59
- T+20 · 2mo ago +33.97%α +35.92% · $2.80
- T+60 · 5d ago −33.01%α −31.46% · $1.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned merger with Scipher Medicine to advance nebokitug into a Phase 2 RA trial is progressing, with closing expected by year-end. The significant EPS miss and lack of revenue highlight the pre-revenue clinical-stage nature of the company, but the merger catalyst provides a potential value inflection point.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.24 missed consensus of $0.00 by 51.8%
- No revenue reported for the quarter
- Planned merger with Scipher Medicine to assess nebokitug in Phase 2 RA trial continues, closing expected by year-end
- Market cap of $14M with 88% analyst bullish rating
Financial Impact
EPS miss of -$0.24 vs $0 consensus; no revenue; merger value undisclosed
Risk Factors
- Merger may not close as expected
- Nebokitug Phase 2 RA trial could fail
- Cash burn without revenue may require dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3347616 |
Track record
15 reports on CMMB
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Viewing Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers